La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
CytomX Therapeutics Croissance future
Future contrôle des critères 0/6
Les revenus et les bénéfices de CytomX Therapeutics devraient diminuer respectivement de 15.2% et de 27.2% par an, tandis que le BPA devrait croître de diminuer de 26.1% par an.
Informations clés
-27.2%
Taux de croissance des bénéfices
-26.1%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 30.3% |
Taux de croissance des recettes | -15.2% |
Rendement futur des capitaux propres | n/a |
Couverture par les analystes | Good |
Dernière mise à jour | 09 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments
Jul 15The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%
Jun 15We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now
May 09CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling
May 02CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 27CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Apr 25CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%
Mar 05CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Jan 19There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise
Nov 26We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely
Nov 17Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 29Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?
Feb 13Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%
Nov 10CytomX Therapeutics to cut workforce by about 40%
Jul 13CytomX says phase 2 study of breast cancer antibody treatment met main goal
Jul 06Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Jun 08Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?
Feb 10CytomX: Pullbacks Are Opportunities
Dec 14CytomX: Solving A Critical Problem In The High-Value ADC Space
Sep 15We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate
Aug 11Checking In On CytomX Therapeutics
Jun 13Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being
Jun 10Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 67 | -57 | -37 | N/A | 2 |
12/31/2025 | 73 | -54 | -40 | -66 | 5 |
12/31/2024 | 100 | -33 | -44 | -65 | 6 |
6/30/2024 | 120 | 11 | -86 | -86 | N/A |
3/31/2024 | 119 | 17 | -92 | -91 | N/A |
12/31/2023 | 101 | -1 | -57 | -56 | N/A |
9/30/2023 | 95 | -10 | -36 | -35 | N/A |
6/30/2023 | 79 | -42 | -52 | -51 | N/A |
3/31/2023 | 68 | -71 | -61 | -60 | N/A |
12/31/2022 | 53 | -99 | -113 | -111 | N/A |
9/30/2022 | 21 | -149 | -142 | -141 | N/A |
6/30/2022 | 27 | -143 | -138 | -136 | N/A |
3/31/2022 | 30 | -132 | -132 | -130 | N/A |
12/31/2021 | 37 | -116 | -121 | -119 | N/A |
9/30/2021 | 66 | -72 | -107 | -105 | N/A |
6/30/2021 | 66 | -64 | -103 | -100 | N/A |
3/31/2021 | 67 | -61 | 23 | 25 | N/A |
12/31/2020 | 68 | -65 | 3 | 5 | N/A |
9/30/2020 | 92 | -54 | -9 | -7 | N/A |
6/30/2020 | 85 | -63 | -8 | -5 | N/A |
3/31/2020 | 78 | -76 | -154 | -151 | N/A |
12/31/2019 | 27 | -133 | -144 | -140 | N/A |
9/30/2019 | 61 | -99 | -144 | -140 | N/A |
6/30/2019 | 62 | -99 | -126 | -122 | N/A |
3/31/2019 | 75 | -83 | -105 | -100 | N/A |
12/31/2018 | 60 | -85 | -79 | -76 | N/A |
9/30/2018 | 75 | -52 | -28 | -25 | N/A |
6/30/2018 | 87 | -39 | -27 | -25 | N/A |
3/31/2018 | 74 | -50 | N/A | 175 | N/A |
12/31/2017 | 72 | -43 | N/A | 170 | N/A |
9/30/2017 | 51 | -58 | N/A | 150 | N/A |
6/30/2017 | 30 | -62 | N/A | 142 | N/A |
3/31/2017 | 24 | -51 | N/A | -16 | N/A |
12/31/2016 | 15 | -59 | N/A | -2 | N/A |
9/30/2016 | 11 | -57 | N/A | -12 | N/A |
6/30/2016 | 9 | -57 | N/A | -6 | N/A |
3/31/2016 | 8 | -50 | N/A | -28 | N/A |
12/31/2015 | 8 | -42 | N/A | -27 | N/A |
9/30/2015 | 8 | -36 | N/A | -24 | N/A |
6/30/2015 | 8 | -26 | N/A | 30 | N/A |
3/31/2015 | 6 | -24 | N/A | 31 | N/A |
12/31/2014 | 5 | -35 | N/A | 32 | N/A |
12/31/2013 | 1 | -19 | N/A | -8 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: Les bénéfices de CTMX devraient diminuer au cours des 3 prochaines années ( -27.2% par an).
Bénéfices vs marché: Les bénéfices de CTMX devraient diminuer au cours des 3 prochaines années ( -27.2% par an).
Croissance élevée des bénéfices: Les bénéfices de CTMX devraient baisser au cours des trois prochaines années.
Chiffre d'affaires vs marché: Les revenus de CTMX devraient diminuer au cours des 3 prochaines années ( -15.2% par an).
Croissance élevée des revenus: Les revenus de CTMX devraient diminuer au cours des 3 prochaines années ( -15.2% par an).
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CTMX devrait être élevé dans 3 ans